Dominique BaetenMikkel ØstergaardJames Cheng-Chung WeiJoachim SieperPentti JärvinenLai-Shan TamCarlo SalvaraniTae-Hwan KimAlan SolingerYakov DatsenkoChandrasena PamulapatiSudha VisvanathanDavid B HallStella AslanyanPaul SchollSteven J Padula2026-01-292026-01-292018-0910.1136/annrheumdis-2018-213328https://scholars.csmu.edu.tw/handle/123456789/3726Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 studyjournal-article